Kansas Bioscience Authority

KBA is governed by a board of directors appointed by the Kansas governor and legislative leaders. The board sets investment strategy and approves major commitments. Day-to-day investment management is handled by a professional staff, though specific named executives are not publicly listed. (per KBA state statute, 2004)

KBA sources deals through its network of university research partners — including the University of Kansas Medical Center and Kansas State University's College of Veterinary Medicine — as well as through direct outreach to Kansas-based bioscience startups. It also receives referrals from venture capital firms active in the region. (per Kansas City Business Journal, 2022)

KBA is a hybrid — a state-chartered public authority that operates with venture-like investment discipline. It can take equity positions, make direct investments, and seek financial returns, but it was created by state legislation and is beholden to public oversight. Its mandate is economic development, not maximizing return. (per KBA enabling statute, 2004)

KBA invests across the full spectrum of bioscience development — from early-stage university research grants and seed rounds to growth-stage venture capital and commercialization support. It often fills gaps where private capital is scarce, such as translational research or first-in-human clinical trials. (per Kansas City Business Journal, 2022)

KBA's mandate limits investments to bioscience and related technologies. It does not invest in software, financial services, real estate, or other non-bioscience sectors. Within bioscience, it focuses on human and animal health, agriculture, and industrial biotechnology. (per KBA enabling statute, 2004)